Engineering of DNA-Encoded PCSK9 Monoclonal Antibodies as Novel Lipid-Lowering Therapeutics

被引：0
|
作者：
Khoshnejad, Makan [1 ]
Patel, Ami [1 ]
Kudchodkar, Sagar [1 ]
Wojtak, Krzysztof [1 ]
Muthumani, Kar [1 ]
Weiner, David B. [1 ]
机构：
[1] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA
来源：
MOLECULAR THERAPY | 2018年 / 26卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
610
引用
收藏
页码：282 / 282
页数：1
相关论文
共 50 条
  • [1] Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics
    Khoshnejad, Makan
    Patel, Ami
    Wojtak, Krzysztof
    Kudchodkar, Sagar B.
    Humeau, Laurent
    Lyssenko, Nicholas N.
    Rader, Daniel J.
    Muthumani, Kar
    Weiner, David B.
    MOLECULAR THERAPY, 2019, 27 (01) : 188 - 199
  • [2] Lipid-lowering drugs and PCSK9
    Millan Nunez-Cortes, Jesus
    Mostaza Prieto, Jose M.
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2016, 28 : 9 - 13
  • [3] PCSK9 antibodies: A new class of lipid-lowering drugs
    Gouni-Berthold, Ioanna
    ATHEROSCLEROSIS SUPPLEMENTS, 2015, 18 : 21 - 27
  • [4] LIPID-LOWERING THERAPY WITH PCSK9 MONOCLONAL ANTIBODIES DURING THE COVID-19 PANDEMIC: NOVEL INSIGHTS AND PERSPECTIVES
    Leggio, M.
    Aiello, A.
    Di Fusco, S.
    Mocini, D.
    Colivicchi, F.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0C) : C103 - C103
  • [5] Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Eze-timibe and PCSK9 Monoclonal Antibodies
    Ali, Adel Hajj
    Younis, Nour
    Abdallah, Rola
    Shaer, Farah
    Dakroub, Ali
    Ayoub, Mohammed Akli
    Iratni, Rabah
    Yassine, Hadi Mohamad
    Zibara, Kazem
    Orekhov, Alexander
    El-Yazbi, Ahmed Fawzy
    Eid, Ali H.
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (36) : 7427 - 7445
  • [6] Lipid-Lowering Agents Targets Beyond PCSK9
    Hegele, Robert A.
    Tsimikas, Sotirios
    CIRCULATION RESEARCH, 2019, 124 (03) : 386 - 404
  • [7] The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies
    Lambert, Gilles
    Thedrez, Aurelie
    Croyal, Mikael
    Ramin-Mangata, Stephane
    Couret, David
    Diotel, Nicolas
    Nobecourt-Dupuy, Estelle
    Krempf, Michel
    LeBail, Jean Christophe
    Poirier, Bruno
    Blankenstein, Jorg
    Villard, Elise F.
    Guillot, Etienne
    CLINICAL SCIENCE, 2017, 131 (04) : 261 - 268
  • [8] Tafolecimab, a Third Monoclonal Antibody for PCSK9 as the Novel Lipid-Lowering Drug Around the World: A Narrative Review
    Liu, Hui-Hui
    Li, Sha
    Li, Jian-Jun
    DRUGS, 2025,
  • [9] Statins and PCSK9 inhibitors: A new lipid-lowering therapy
    Gallego-Colon, Enrique
    Daum, Aner
    Yosefy, Chaim
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 878
  • [10] PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?
    Cainzos-Achirica, Miguel
    Martin, Seth S.
    Cornell, John E.
    Murow, Cynthia D.
    Guallar, Eliseo
    ANNALS OF INTERNAL MEDICINE, 2015, 163 (01) : 64 - 65
12345